Actively Recruiting
Phase II Study of Weekly GL0034 Injections to Treat Overweight or Obese Adults With Type II Diabetes
Led by Sun Pharmaceutical Industries Limited · Updated on 2026-03-18
285
Participants Needed
21
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and tolerability of GL0034 in adults with type II diabetes mellitus who are overweight or obese and have weight-related health issues. This phase II, randomized, double-blind, placebo-controlled study aims to assess how GL0034 affects blood sugar control, specifically measuring changes in HbA1c levels over time. The study includes participants who have had type II diabetes for at least six months and meet specific blood sugar and body mass index BMI criteria. Participants will be randomly assigned to one of five groups four groups receiving different dose levels of GL0034 and one group receiving a placebo. The treatment begins with a dose up-titration period lasting about 20 weeks, where doses are gradually increased. After reaching the final dose, participants continue weekly subcutaneous injections of their assigned dose through Week 48. The placebo group follows a similar schedule with sham injections. Throughout the study, participants will undergo regular blood tests, including fasting blood draws and blood sugar monitoring using a home glucometer. Researchers will measure changes in HbA1c levels at Weeks 36 and 48, as well as track body weight, BMI, and the proportion of participants achieving specific weight loss milestones. Participants will also record responses using an electronic patient-reported outcomes device to support data collection. Safety and tolerability will be monitored throughout the trial, which is expected to conclude in August 2027.
CONDITIONS
Brief Title
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Research Team
H
Head, Regulatory Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here